Compass Pathways Plc

NASDAQ: CMPS
$8.42
-$0.11 (-1.3%)
Closing price April 18, 2024
Compass Pathways Plc is a pioneering mental health care company based in London, focusing on creating innovative treatments. It is known for developing COMP360, a psilocybin therapy, which is currently undergoing advanced clinical trials. This therapy aims to address severe conditions such as treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa. Founded in 2020, Compass Pathways is at the forefront of exploring psychedelic-based treatments to improve mental health.

5 of Cathie Wood's Sizzling ARK Investment Stocks Are Buy Rated and Trading Under $10
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Lee Jackson
Published:

Wednesday's Top Analyst Upgrades and Downgrades: AppLovin, Charles Schwab, First Solar, Halliburton, Monster Beverage, QuantumScape, Union Pacific and More
Wednesday's top analyst upgrades and downgrades included AppLovin, Arista Networks, Charles Schwab, First Solar, Global Payments, Halliburton, Monster Beverage, NXP Semiconductor, QuantumScape, Union...
Lee Jackson
Published:

5 Psychedelic Therapeutics Decisions Coming in 2022
Here is a look of a few of the biggest clinical trial and FDA updates in regards to psychedelics to watch for in 2022.
Chris Lange
Published:

Time to Buy the Magic Stocks? Magic Mushrooms, That Is.
Here's a quick look at six publicly traded companies developing ways to use psychedelics to treat mental health issues.
Paul Ausick
Published: